The etiology of sporadic acute hepatitis was studied in 334 consecutive patients from Taiwan (237 men and 97 women, aged 16-81 years), with emphasis on the role of hepatitis C virus (HCV), hepatitis E virus (HEV), and GB virus-C/hepatitis G virus (GBV-C/HGV) in acute non-A, non-B (NANB) hepatitis an
Detection of antibodies to E2-protein of GB virus-C/hepatitis G virus in patients with acute posttransfusion hepatitis
โ Scribed by Hwang, Shinn-Jang; Lu, Rei-Hwa; Chan, Cho-Yu; Chang, Full-Young; Lee, Shou-Dong
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 171 KB
- Volume
- 57
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
โฆ Synopsis
GB virus-C/hepatitis G virus (GBV-C/HGV) is an RNA virus that can be transmitted by transfusion with the diagnosis based on the detection of serum GBV-C/HGV RNA by reverse transcriptionpolymerase chain reaction. In order to evaluate the role of antibodies to the E2 protein (anti-E2) of GBV-C/HGV in patients with acute posttransfusion hepatitis, anti-E2 was measured in one patient with acute GBV-C/HGV infection, five patients with acute GBV-C/HGV and hepatitis C virus (HCV) coinfection, and four patients with positive pretransfusion GBV-C/HGV RNA who were superinfected with HCV after transfusion. One patient with acute GBV-C/HGV infection remained GBV-C/HGV RNA-positive 18 months after transfusion and did not develop anti-E2. Among five patients with acute GBV-C/HGV and HCV coinfection, one lost GBV-C/HGV RNA 28 months after transfusion and developed anti-E2 independent of serum alanine aminotranferase levels. The other four patients remained GBV-C/ HGV RNA-positive and anti-E2-negative at the end of follow-up. Among four patients with positive pretransfusion GBV-C/HGV RNA and superinfected with HCV, one lost GBV-C/HGV RNA 2 months and one 10 months after superinfection and subsequently developed anti-E2. The other two patients remained GBV-C/HGV RNA-positive without anti-E2 at the end of follow-up. Sixtyfive samples tested were mutually and exclusively positive for either GBV-C/HGV RNA or anti-E2; only one sample was positive for both GBV-C/HGV RNA and anti-E2. In conclusion, the development of anti-E2 of GBV-C/HGV usually indicates the clearance of serum GBV-C/HGV RNA in patients with acute posttransfusion hepatitis.
๐ SIMILAR VOLUMES
The recently identified hepatitis G virus (HGV, also named GB virus-C, GBV-C) appears to have similarities to hepatitis C virus and other flaviviridae. To better understand its clinical significance and hepatotropism, we collected liver tissue and matched serum samples from 56 patients undergoing li
Prevalence of GBV-C/HGV was determined in a cohort of HIV-infected patients, via a reverse transcription-polymerase chain reaction detection of RNA in serum, amplifying the NS5 region of GBV-C/HGV genome. GBV-C/HGV RNA was detected in 143 (37.7%) of 379 patients, with similar results in the differen
GBV-C/Hepatitis G virus (GBV-C/HGV) is a newly discovered viral agent, found widely among healthy blood donors and among individuals at risk of parenterally transmitted infections. GBV-C/HGV is found frequently in coinfection with HCV. A population of 109 HCV positive patients was examined for the p
Of 74 patients who were infected with hepatitis C virus (HCV) and received interferon, 12 (16%) were positive for RNA of GB virus C (GBV-C). RNA of GBV-C was determined in sera from the co-infected patients retrospectively, and the effect of interferon on GBV-C was compared with that on HCV in them.